Pharma BD Deal Intelligence

Sumitovant Biopharma / Myovant Sciences

2022 · Acquisition/Merger · $1.7B · Complete

Announcement Sentiment

50

Neutral / mixed

Outcome Score

60

Largely worked — most objectives met.

Sumitovant acquired remaining Myovant Sciences shares for $1.7B.

Key facts

Announced Dec 16, 2022
Closed Mar 10, 2023
Deal value $1.7B
Deal type Acquisition/Merger
Therapeutic area Women's Health

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals